A phase‐1, open‐label, single‐dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment

av Csonka, Denes, Hazell, Katharine, Waldron, Edward, Lorenzo, Sebastien, Duval, Vincent, Trandafir, Lucia, Kobalava, Zhanna D.
I publikationen J Clin Pharmacol (2016)

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

av Massacesi, Cristian, Di Tomaso, Emmanuelle, Urban, Patrick, Germa, Caroline, Quadt, Cornelia, Trandafir, Lucia, Aimone, Paola, Fretault, Nathalie, Dharan, Bharani, Tavorath, Ranjana, Hirawat, Samit
I publikationen Onco Targets Ther (2016)

ATNT-12 PHASE I, TWO-STAGE, OPEN-LABEL, DOSE-ESCALATION STUDY OF BUPARLISIB (BKM120) IN COMBINATION WITH ADJUVANT TEMOZOLOMIDE (TMZ) AND WITH CONCOMITANT RADIATION THERAPY (RT) AND...

av Rodon, Jordi, Rosenthal, Mark, Mason, Warren, Segura, Pedro Perez, Beck, Joseph T., Hirte, Holger, DeGroot, John F., Trandafir, Lucia, Pognan, Nathalie, Yang, Lin, Kanwal, Charu, Wen, Patrick Y.
I publikationen Neuro Oncol (2015)

Re‐treatment with radium‐223: 2‐year follow‐up from an international, open‐label, phase 1/2 study in patients with castration‐resistant prostate cancer and bone metastases...

av Sartor, Oliver, Heinrich, Daniel, Mariados, Neil, Méndez Vidal, Maria José, Keizman, Daniel, Thellenberg Karlsson, Camilla, Peer, Avivit, Procopio, Giuseppe, Frank, Stephen J., Pulkkanen, Kalevi, Rosenbaum, Eli, Severi, Stefano, Trigo, José, Trandafir, Lucia, Wagner, Volker, Li, Rui, Nordquist, Luke T.
I publikationen Prostate (2019)